From PvP Biologics Raises $35M in a Lab-to-Pharma Deal with Takeda:

KumaMax Enzyme (Image by Vikram Mulligan:Univ. Wash., used with permission)

KumaMax Enzyme (Image by Vikram Mulligan:Univ. Wash., used with permission)—

Computer-generated image of KumaMax Enzyme (Image by Vikram Mulligan:Univ. Wash., used with permission)

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
IBM Watson Health Data in Action – Epidemiology Studies
With data from IBM Watson Health, epidemiologists can describe treatment patterns, persistence & adherence to therapy
IBM Watson

Sponsored · Whitepaper
CMC in Drug Development and Life Cycle Management
CMC in Drug Development and Life Cycle Management
PRA Health Sciences

From Our Partners · Special Report
Robert Langer reveals secrets to early-stage biotech success
Advice for funding and future transformational opportunities

Xconomy on Demand

We offer a number of ways to subscribe for free!